EDS-FLU在伴或不伴既往鼻窦手术的慢性鼻窦炎患者中的疗效:ReOpen1和ReOpen2随机对照试验
ReOpen1/ReOpen2两项24周随机试验的汇总分析,按手术状态分层比较呼气递送系统氟替卡松(EDS-FLU)与安慰剂在慢性鼻窦炎患者中的疗效。未手术组332例、既往手术组215例,EDS-FLU在症状评分、鼻塞、鼻窦浑浊体积百分比及SNOT-22总分上均较安慰剂显著改善(p<0.05),两个手术亚组间无统计学显著差异。
要点
- EDS-FLU在未手术和既往手术的慢性鼻窦炎患者中均较安慰剂显著改善症状与鼻窦浑浊(p<0.05)。
- 两个手术亚组之间在任一EDS-FLU剂量下均未观察到统计学显著差异。
- 基线均值CSS=5.8、APOV=67.2%,提示入组患者为中重度疾病。
核心结论
- EDS-FLU改善了伴或不伴既往内镜鼻窦手术的慢性鼻窦炎患者的症状、鼻窦浑浊和生活质量,提示EDS-FLU在这两类人群中均可能发挥作用。
研究设计与样本
- ReOpen1和ReOpen2两项24周随机对照试验的汇总数据分析,按手术状态分层。
- 未手术组n=332,既往手术组n=215。
- 比较EDS-FLU与EDS-安慰剂。
主要发现
- 第4、8、12周联合症状评分(CSS)最小二乘均值变化:未手术组-0.68 vs -1.42,既往手术组-0.70 vs -1.87(p<0.05)。
- 第4、8、12周鼻塞评分最小二乘均值变化:未手术组-0.24 vs -0.59,既往手术组-0.24 vs -0.69(p<0.05)。
- 第24周SNOT-22总分最小二乘均值变化:未手术组-7.56 vs -18.30,既往手术组-10.72 vs -18.74(p<0.05)。
- 筛窦/上颌窦CT平均浑浊体积百分比(APOV)也观察到相似结果(p<0.05)。
- 两个手术亚组之间在任一EDS-FLU剂量下均未观察到统计学显著差异。
关键数值与推荐
- 基线平均CSS=5.8,平均APOV=67.2%。
- 主要结局为第4、8、12周CSS和鼻塞评分,以及第24周APOV和SNOT-22总分的最小二乘均值较基线变化。
临床怎么用
- 原文未据此给出推荐,结论为EDS-FLU改善了伴或不伴既往内镜鼻窦手术的慢性鼻窦炎患者的症状、鼻窦浑浊和生活质量,提示其在这两类人群中均可能发挥作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The inability of topical medications to reach sinus cavities is a potential reason for lack of efficacy in chronic rhinosinusitis (CRS). One purpose of endoscopic sinus surgery (ESS) is to enable delivery of medications into the sinus cavities. The exhalation delivery system with fluticasone (EDS-FLU; XHANCE) creates unique biomechanics that enable deposition of intranasal corticosteroid into sinuses and sinus drainage pathways but may have differing efficacy in operated versus unoperated sinuses. Two 24-week randomized trials (ReOpen1/2) evaluated EDS-FLU versus EDS-placebo in patients with CRS, stratified by surgical status. METHODS: Surgery-naive (n = 332) and prior-surgery (n = 215) patient groups were analyzed as pooled data from ReOpen1/2. Outcome measures (least-squares mean change from baseline) included combined symptom score (CSS) and congestion score at weeks 4, 8, and 12 and average of percentages of opacified volume (APOV) of ethmoid/maxillary sinuses on CT and Sinonasal Outcome Test 22 (SNOT-22) total score at week 24. RESULTS: Baseline scores suggested moderate-severe disease: mean CSS = 5.8; APOV = 67.2%. EDS-FLU produced significant improvement versus placebo (p < 0.05): CSS (surgery-naive, -0.68 vs. -1.42; prior ESS, -0.70 vs. -1.87); congestion (surgery-naive, -0.24 vs. -0.59; prior ESS, -0.24 vs. -0.69); and SNOT-22 (surgery-naive, -7.56 vs. -18.30; prior ESS, -10.72 vs. -18.74). Similar results were observed for APOV (p < 0.05). No statistically significant difference was observed between surgery subgroups with either EDS-FLU dose. CONCLUSION: EDS-FLU improved symptoms, sinus opacification, and quality of life in patients with CRS with or without prior ESS, suggesting a role for EDS-FLU in both populations.
引用
- Wise SK, Adappa ND, Chandra RK, et al. EDS-FLU efficacy in patients with chronic rhinosinusitis with or without prior sinus surgery in ReOpen1 and ReOpen2 randomized controlled trials. Int Forum Allergy Rhinol. 2024. PMID: 39186196. doi:10.1002/alr.23434
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。